In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1314-1316

  Sugar, Alan M ^a   Liu, Xiu Ping ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLASTOMYCOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FUNGICIDAL ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030001767     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1314     Document Type: Article

References (10)

1. Galgiani. J. N., M. L. Lewis, and T. Peng. 1995. In vitro studies of a new azole antifungal drug, SCH 56592, abstr. F63, p. 124. In abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Harvey, R. P., E. S. Schmid, C. C. Carrington, and D. A. Stevens. 1978. Mouse model of pulmonary blastomycosis. utility, simplicity, and quantitative parameters. Am. Rev. Respir. Dis. 117:695-703.
3. Mangino, J. E., and P. G. Pappas. 1995. Itraconazole for the treatment of histoplasmosis and blastomycosis. Int. J. Antimicrob. Agents 5:219-225.
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard Document M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa
5. Pappas, P., R. W. Bradsher, S. W. Chapman, C. A. Kauffman, A. Dine, G. A. Cloud, W. E. Dismukes, and National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1995. Treatment of blastomycosis with fluconazole: a pilot study Clin. Infect. Dis 20:267-271.
6. Parmegiani, R., A. Cacciapuoti, D. Loebenberg, B. Antonacci, C. Norris, T. Yarosh-Tomaine, M. Michalski, R. S. Hare, and G. H. Miller. 1995 In vitro activity of SCH 56592, a new antifungal agent, abstr. F62, p. 123. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington. D C.
7. Perfect, J. R., and W. A. Schell. 1995. In vitro efficacy of the azole, SCH 56592, compared to amphotericin B, fluconazole, and itraconazole versus Cryptococcus neoformans, abstr. F64, p. 124 In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Stevens, D. A., E. Brummer, J. G. McEwen, and A. M. Perlman. 1990. Comparison of fluconazole and ketocouazole in experimental murine blastomycosis. Rev. Infect Dis. 12:S304-S306.
9. Sugar, A. M., and X.-P. Liu. 1995. Comparison of three methods of antifungal susceptibility testing with the proposed NCCLS standard broth macrodilution assay: lack of effect of phenol red. Diagn Microbiol. Infect. Dis. 21:129-133.
10. Sugar, A. M., and M. Picard. 1995. Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent. Antimicrob Agents Chemother. 39:996-997